Medlab Clinical (Medlab Clinical) DeferredTaxAndRevenue : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Medlab Clinical DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Medlab Clinical's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

Medlab Clinical DeferredTaxAndRevenue Historical Data

The historical data trend for Medlab Clinical's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical DeferredTaxAndRevenue Chart

Medlab Clinical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

DeferredTaxAndRevenue

Get a 7-Day Free Trial

Medlab Clinical Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
DeferredTaxAndRevenue	Get a 7-Day Free Trial												-	-	-	-	-

Medlab Clinical DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlab Clinical (Medlab Clinical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (OTCPK:MDBBF) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.